AHA GUIDELINES Bundle (free trial)

AHA/ASA Early Management of Acute Ischemic Stroke 2026

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1542862

Contents of this Issue

Navigation

Page 27 of 57

28 General Supportive Early Management 4.6.3. Extended Time Windows for Intravenous Thrombolysis COR LOE Recommendations 2a B-R 1. In patients with AIS who (a) have unknown time of onset and are within 4.5 hours from symptom recognition and (b) have an MRI-DWI lesion smaller than one-third of the MCA territory and no marked signal change on FLAIR, IVT administered within 4.5 hours of stroke symptom recognition can be beneficial to improve functional outcomes. 2a B-R 2. (New and of High Impact) In patients with AIS who have salvageable ischemic penumbra detected on automated perfusion imaging and who (a) awake with stroke symptoms within 9 hours from the midpoint of sleep or (b) are 4.5–9 hours from last known well, IV thrombolysis may be reasonable to improve functional outcomes. 2b B-R 3. In patients with AIS due to LVO with salvageable ischemic penumbra, presenting within 4.5 to 24 hours from symptom onset or last known well, and who cannot receive EVT, treatment with IVT directed by individuals with expertise in thrombolytic stroke care may be beneficial to improve functional outcomes. 4.6.4. Other IV Fibrinolytics and Sonothrombolysis COR LOE Recommendations Other IV Fibrinolytics 2b B-R 1. In eligible patients with AIS presenting within 4.5 hours from last known normal and not undergoing EVT, IV reteplase, instead of alteplase, may be considered to increase the odds of excellent functional outcome at 90 days. 2b B-R 2. In eligible patients with AIS within 4.5 hours from last known normal and not undergoing EVT, IV mutant prourokinase, instead of alteplase, may be considered due to lower odds of bleeding and noninferiority for odds of excellent functional outcome at 90 days. 3: No benefit A 3. In eligible patients with AIS presenting within 3 to 9 hours from last known normal, IV desmoteplase is not recommended for improving functional independence at 90 days. 3: No benefit B-R 4. In eligible patients with AIS within 4.5 hours from last known normal, IV mutant prourokinase in conjunction with low-dose alteplase is not recommended to improve functional outcomes.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - AHA/ASA Early Management of Acute Ischemic Stroke 2026